Artificial Intelligence is Transforming the Medical and Biotechnology Sector
Health leaders gathered at an event in Cambridge stated that artificial intelligence is accelerating drug discovery and changing patient care approaches.
Speaking at an event in Cambridge, three healthcare industry leaders discussed how artificial intelligence is reshaping processes in medicine and biotechnology from the laboratory to the clinic.
New Era in Drug Discovery
Yvonne Hao, Chief Operating Officer of Flagship Pioneering, stated that artificial intelligence allows all experiments to be conducted in parallel and significantly accelerates the drug discovery process.
A Power That Challenges Scientific Assumptions
Yesmean Wahdan from Bayer noted that the greatest value of artificial intelligence is not just its computational speed, but also enabling scientists to question deeply rooted assumptions in cell, gene therapy, and oncology.
Models Predicting Cancer Risk
Connie Lehman from Clairity shared that they received an important FDA approval for an artificial intelligence model that predicts a woman's future breast cancer risk from standard mammography images without increasing the workload of radiologists.
The Role of Experts and Future Expectations
Experts emphasized that artificial intelligence will not completely replace scientists or doctors, but rather serve as a tool that uncovers patterns and questions humans alone cannot reach.
Industry leaders stated that the role of artificial intelligence in life sciences is still in its infancy and that further changes are expected in drug development and diagnostics.